摘要
衰老最初是由有限生命周期的正常细胞识别的,是每一个DNA循环周期中端粒缩短的结果。
关键词: 衰老,肿瘤细胞,化疗,DNA损伤,p53,p21WAF-1, p16INK4A
图形摘要
Current Drug Targets
Title:Is Senescence Reversible?
Volume: 17 Issue: 4
Author(s): Shweta Chakradeo, Lynne W. Elmore and David A. Gewirtz
Affiliation:
关键词: 衰老,肿瘤细胞,化疗,DNA损伤,p53,p21WAF-1, p16INK4A
摘要: Senescence was originally identified by the finite lifespan of normal cells that is a consequence of telomere shortening with each cycle of DNA replication. Cells undergoing replicative senescence display pronounced morphological and biochemical changes such as flattening and/or enlargement, increases in p21WAF1 and/or p16INK4A, a senescence-associated secretory phenotype, and often senescence-associated heterochromatic foci. Senescence also occurs in tumor cells in response to various forms of chemotherapy or radiation (therapy-induced senescence), which could be the basis for prolonged or (ideally) permanent growth arrest. Alternatively, therapy-induced senescence could represent a means whereby tumor cells evade the potential toxicity of chemotherapy and radiation, allowing for the eventual re-emergence or escape from senescence that could lead to disease recurrence. This review discusses the experimental data in the literature that support the premise that senescence is potentially reversible through the inactivation of p53, p16INK4A and/or Rb, over-expression of Cdc2/cdk1 and survivin, the development of polyploidy, the survival of cancer stem cells and/or restoration of the nuclear landscape. If senescence is truly reversible, then the re-emergence of tumor cells from senescent arrest induced by chemotherapy or radiation could represent a barrier to the development of effective and curative cancer therapies.
Export Options
About this article
Cite this article as:
Shweta Chakradeo, Lynne W. Elmore and David A. Gewirtz , Is Senescence Reversible?, Current Drug Targets 2016; 17 (4) . https://dx.doi.org/10.2174/1389450116666150825113500
DOI https://dx.doi.org/10.2174/1389450116666150825113500 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia
Protein & Peptide Letters Multiple Forms of Proteasomes and their Role in Tumor Fate
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design Integrated Genomic and Pharmacological Approaches to Identify Synthetic Lethal Genes as Cancer Therapeutic Targets
Current Molecular Medicine MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry Gender Disparity in Pediatric Diseases
Current Molecular Medicine RNA Interference (RNAi) Patents and Human Health Related Applications of RNAi
Recent Patents on DNA & Gene Sequences Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Protein Serine/Threonine Phosphotase-1 is Essential in Governing Normal Development of Vertebrate Eye
Current Molecular Medicine Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Antiviral Medication in Sexually Transmitted Diseases. Part I: HSV, HPV
Mini-Reviews in Medicinal Chemistry E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery HPV Viral Activity by mRNA-HPV Molecular Analysis to Screen the Transforming Infections in Precancer Cervical Lesions
Current Pharmaceutical Biotechnology Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design